Amicus Therapeutics, Inc. (FOLD)

Market Cap	4.55B +132.9%
Revenue (ttm)	634.21M +20.0%
Net Income	-27.11M
EPS	-0.09
Shares Out	314.00M
PE Ratio	n/a
Forward PE	39.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,285,334
Open	14.49
Previous Close	n/a
Day's Range	14.49 - 14.50
52-Week Range	5.51 - 14.50
Beta	0.48
Analysts	Buy
Price Target	27.25 (+88.06%)
Earnings Date	May 6, 2026

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecu...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 31, 2007
• Employees: 511
• Stock Exchange: NASDAQ
• Ticker Symbol: FOLD
• Website: https://amicusrx.com

Financial Performance

In 2025, Amicus Therapeutics's revenue was $634.21 million, an increase of 20.05% compared to the previous year's $528.30 million. Losses were -$27.11 million, -51.68% less than in 2024.

Analyst Summary

According to 9 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price target is $27.25, which is an increase of 88.06% from the latest price.

Price Target

$27.25

(88.06% upside)

Analyst Consensus: Buy